DK3677278T3 - Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf - Google Patents

Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf Download PDF

Info

Publication number
DK3677278T3
DK3677278T3 DK19185896.8T DK19185896T DK3677278T3 DK 3677278 T3 DK3677278 T3 DK 3677278T3 DK 19185896 T DK19185896 T DK 19185896T DK 3677278 T3 DK3677278 T3 DK 3677278T3
Authority
DK
Denmark
Prior art keywords
tgfbeta1
inhibitors
isoform selective
isoform
selective
Prior art date
Application number
DK19185896.8T
Other languages
English (en)
Inventor
Abhishek Datta
Allan Capili
Thomas Schurpf
Constance Martin
Kevin B Dagbay
Christopher Chapron
Stefan Wawersik
Christopher Littlefield
Gregory J Carven
Alan Buckler
Susan Lin
Justin W Jackson
Anthony Cooper
Andrew Avery
Matthew Salotto
Caitlin Stein
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Application granted granted Critical
Publication of DK3677278T3 publication Critical patent/DK3677278T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DK19185896.8T 2018-07-11 2019-07-11 Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf DK3677278T3 (da)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862696774P 2018-07-11 2018-07-11
US201862696752P 2018-07-11 2018-07-11
US201862718196P 2018-08-13 2018-08-13
US201862722081P 2018-08-23 2018-08-23
US201862737534P 2018-09-27 2018-09-27
US201862757917P 2018-11-09 2018-11-09
US201862758180P 2018-11-09 2018-11-09
US201962810263P 2019-02-25 2019-02-25
US201962827552P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
DK3677278T3 true DK3677278T3 (da) 2022-01-10

Family

ID=67437706

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19185896.8T DK3677278T3 (da) 2018-07-11 2019-07-11 Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf

Country Status (14)

Country Link
US (3) US11130803B2 (da)
EP (2) EP4019046A1 (da)
CY (1) CY1125076T1 (da)
DK (1) DK3677278T3 (da)
ES (1) ES2905160T3 (da)
HR (1) HRP20212034T1 (da)
HU (1) HUE056501T2 (da)
LT (1) LT3677278T (da)
MA (1) MA52165A (da)
PL (1) PL3677278T3 (da)
PT (1) PT3677278T (da)
RS (1) RS62914B1 (da)
SI (1) SI3677278T1 (da)
SM (1) SMT202100703T1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
US20230057012A1 (en) * 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
TWI867190B (zh) * 2020-03-19 2024-12-21 美商建南德克公司 同功型選擇性抗-TGF-β抗體及其使用方法
WO2022116877A1 (en) * 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
WO2022256723A2 (en) * 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20230144192A1 (en) * 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN114236137A (zh) * 2021-12-17 2022-03-25 中山大学·深圳 一种转化生长因子β的体外检测试剂盒及其应用
CN115501322B (zh) * 2022-09-23 2025-06-10 西南交通大学 用于肿瘤免疫治疗的多肽药物偶联物、载药系统、药物组合系统及应用
WO2025145059A1 (en) * 2023-12-29 2025-07-03 Eureka Therapeutics, Inc. Constructs targeting msln ecd and uses thereof
CN119476445B (zh) * 2025-01-06 2025-04-11 杭州宇泛智能科技股份有限公司 基于大小模型协同智能的模型优化方法及系统

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
JP2018527903A (ja) 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
PE20191661A1 (es) 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
US12358992B2 (en) 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途

Also Published As

Publication number Publication date
EP3677278B1 (en) 2021-11-10
EP3677278A1 (en) 2020-07-08
US20220064275A1 (en) 2022-03-03
PL3677278T3 (pl) 2022-02-28
SI3677278T1 (sl) 2022-01-31
EP4019046A1 (en) 2022-06-29
HUE056501T2 (hu) 2022-02-28
US20250215072A1 (en) 2025-07-03
HRP20212034T1 (hr) 2022-04-01
US12122823B2 (en) 2024-10-22
RS62914B1 (sr) 2022-03-31
LT3677278T (lt) 2022-01-10
CY1125076T1 (el) 2023-06-09
PT3677278T (pt) 2022-02-03
ES2905160T3 (es) 2022-04-07
MA52165A (fr) 2021-06-02
US20200079840A1 (en) 2020-03-12
SMT202100703T1 (it) 2022-01-10
US11130803B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
DK3677278T3 (da) Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
EP4043917C0 (en) DETECTION METHOD AND DEVICE
DK4175951T3 (da) Hpk1-hæmmere og anvendelser
DK3753937T3 (da) Atr-hæmmer og anvendelse deraf
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
EP4061068C0 (en) METHOD AND APPARATUS FOR DETERMINING CLOCK DIFFERENCE
EP3860192A4 (en) Measurement method and device
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3582776T3 (da) Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder
IL283106A (en) Erk inhibitors and uses thereof
IL286248A (en) Tyk2 inhibitors and uses thereof
DK3610005T3 (da) Peptidligase og anvendelse deraf
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3752251T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
IL291217A (en) Usp30 inhibitors and uses thereof
DK3447056T3 (da) Multikinasehæmmerforbindelse, krystalform og anvendelse deraf
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
DK3796979T3 (da) Mir-181-hæmmere og anvendelser deraf
EP4028638C0 (en) METHOD AND APPARATUS FOR MEASURING